180 related articles for article (PubMed ID: 28906338)
1. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years.
Scala M; Koob M; de Buttet S; Bourrinet P; Felices M; Jurkiewicz E
Invest Radiol; 2018 Feb; 53(2):70-79. PubMed ID: 28906338
[TBL] [Abstract][Full Text] [Related]
2. Safety of gadoterate meglumine in children younger than 2 years of age.
Farmakis SG; Hardy AK; Mahmoud SY; Wilson-Flewelling SA; Tao TY
Pediatr Radiol; 2020 May; 50(6):855-862. PubMed ID: 32055917
[TBL] [Abstract][Full Text] [Related]
3. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
Soyer P; Dohan A; Patkar D; Gottschalk A
J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
[TBL] [Abstract][Full Text] [Related]
4. Signal Enhancement and Enhancement Kinetics of Gadobutrol, Gadoteridol, and Gadoterate Meglumine in Various Body Regions: A Comparative Animal Study.
Knobloch G; Frenzel T; Pietsch H; Jost G
Invest Radiol; 2020 Jun; 55(6):367-373. PubMed ID: 31985602
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Safety of Macrocyclic Gadobutrol in Children Aged Younger Than 2 Years Including Term Newborns in Comparison to Older Populations.
Kunze C; Mentzel HJ; Krishnamurthy R; Fleck R; Stenzel M; Bhargava R; Burrowes D; Sutter G; Schultze-Mosgau M; Santiuste M; Hahn G
Invest Radiol; 2016 Jan; 51(1):50-7. PubMed ID: 26340504
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy of Reduced-Dose Gadobutrol Versus Standard-Dose Gadoterate for Contrast-Enhanced MRI of the CNS: An International Multicenter Prospective Crossover Trial (LEADER-75).
Liu BP; Rosenberg M; Saverio P; Weon YC; Peters S; Ardellier FD; Boeckenhoff A; Endrikat J
AJR Am J Roentgenol; 2021 Nov; 217(5):1195-1205. PubMed ID: 34133205
[No Abstract] [Full Text] [Related]
7. A Structured Survey on Adverse Events Occurring Within 24 Hours After Intravenous Exposure to Gadodiamide or Gadoterate Meglumine: A Controlled Prospective Comparison Study.
Parillo M; Sapienza M; Arpaia F; Magnani F; Mallio CA; DʼAlessio P; Quattrocchi CC
Invest Radiol; 2019 Apr; 54(4):191-197. PubMed ID: 30379729
[TBL] [Abstract][Full Text] [Related]
8. Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants.
Enterline DS; Martin KW; Parmar HA; Triulzi FM; Colosimo C
AJNR Am J Neuroradiol; 2019 Dec; 40(12):2001-2009. PubMed ID: 31727753
[TBL] [Abstract][Full Text] [Related]
9. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model.
Robert P; Vives V; Grindel AL; Kremer S; Bierry G; Louin G; Ballet S; Corot C
Radiology; 2020 Jan; 294(1):117-126. PubMed ID: 31660804
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats.
Rasschaert M; Emerit A; Fretellier N; Factor C; Robert P; Idée JM; Corot C
Invest Radiol; 2018 Jun; 53(6):328-337. PubMed ID: 29329151
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study).
Maravilla KR; San-Juan D; Kim SJ; Elizondo-Riojas G; Fink JR; Escobar W; Bag A; Roberts DR; Hao J; Pitrou C; Tsiouris AJ; Herskovits E; Fiebach JB
AJNR Am J Neuroradiol; 2017 Sep; 38(9):1681-1688. PubMed ID: 28663267
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Dynamic Contrast-Enhancement Parameters between Gadobutrol and Gadoterate Meglumine in Posttreatment Glioma: A Prospective Intraindividual Study.
Park JE; Kim JY; Kim HS; Shim WH
AJNR Am J Neuroradiol; 2020 Nov; 41(11):2041-2048. PubMed ID: 33060100
[TBL] [Abstract][Full Text] [Related]
13. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
McWilliams RG; Frabizzio JV; De Backer AI; Grinberg A; Maes BD; Zobel BB; Gottschalk A
J Magn Reson Imaging; 2020 Feb; 51(2):607-614. PubMed ID: 31287213
[TBL] [Abstract][Full Text] [Related]
14. Adverse Reactions to Gadoterate Meglumine: Review of Over 25 Years of Clinical Use and More Than 50 Million Doses.
de Kerviler E; Maravilla K; Meder JF; Naggara O; Dubourdieu C; Jullien V; Desché P
Invest Radiol; 2016 Sep; 51(9):544-51. PubMed ID: 27504794
[TBL] [Abstract][Full Text] [Related]
15. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
Lancelot E
Invest Radiol; 2016 Nov; 51(11):691-700. PubMed ID: 27175546
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time.
Renz DM; Diekmann F; Schmitzberger FF; Pietsch H; Fallenberg EM; Durmus T; Huppertz A; Böttcher J; Bick U; Hamm B; Lawaczeck R
Invest Radiol; 2013 Feb; 48(2):69-78. PubMed ID: 23262793
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.
Hahn G; Sorge I; Gruhn B; Glutig K; Hirsch W; Bhargava R; Furtner J; Born M; Schröder C; Ahlström H; Kaiser S; Moritz JD; Kunze CW; Shroff M; Stokland E; Trnkova ZJ; Schultze-Mosgau M; Reif S; Bacher-Stier C; Mentzel HJ
Invest Radiol; 2009 Dec; 44(12):776-83. PubMed ID: 19858730
[TBL] [Abstract][Full Text] [Related]
18. Safety of gadoterate meglumine in over 1600 children included in the prospective observational SECURE study.
Chang DH; Pracros JP
Acta Radiol; 2019 Nov; 60(11):1450-1456. PubMed ID: 31027425
[TBL] [Abstract][Full Text] [Related]
19. Contrast material-enhanced visualization of the ablation medium for magnetic resonance-monitored ethanol injection therapy: imaging and safety aspects.
Nanz D; Andreisek G; Fröhlich JM; Weishaupt D; Treiber K; Ess S; Pfammatter T
J Vasc Interv Radiol; 2006 Jan; 17(1):95-102. PubMed ID: 16415138
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast-enhanced MR imaging of the prostate: intraindividual comparison of gadoterate meglumine and gadobutrol.
Lee CH; Vellayappan B; Taupitz M; Hamm B; Asbach P
Eur Radiol; 2019 Dec; 29(12):6982-6990. PubMed ID: 31264013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
